Vascular robotics is growing fast and Corindus is the leader here, but Healthineers will need an aggressive sales plan.
Medtronic decides that Solitaire is best played with a partner.
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
With little cash in the bank and creditors soon to start pressing, a trial failure is a disaster for Viveve.
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.